Profitelligence Profitelligence · Filing Ledger Open ABBV research →

Form 8-K · Current Report · Filed 2024-09-10

AbbVie Inc. Updates By-laws and Provides Financial Exhibits

On September 6, 2024, AbbVie Inc. updated its By-laws by amending the address of its registered agent and deleting a section related to a stockholder class action complaint. Additionally, the company provided financial statements and exhibits as part of its 8-K filing.

Filer
AbbVie Inc. ABBV · NYSE
Filed
Accession
0001104659-24-098564
CIK
0001551152
Signal
Medium impactHealthcare

Items reported

Item 5.03

Amendments to Articles of Incorporation or Bylaws

Bylaw Amendment
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$196.42

Next session

-0.9%

Since filing

+27.8%

Latest close

$250.94

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from ABBV reporting the same item, with the next session's move:

Exhibits (1)

About AbbVie Inc.

AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.

Exchange NYSE Industry Drug Manufacturers - General Company website ↗

Never miss another ABBV filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts